肿瘤,Notch信号通路,化学治疗,耐药," /> 肿瘤,Notch信号通路,化学治疗,耐药,"/> Cancer,Notch signaling pathway,Chemotherapy,Drug-resistance

,"/> <span style="font-size:10.5pt;font-family:宋体;">Notch</span><span style="font-size:10.5pt;font-family:宋体;">信号通路与肿瘤耐药的研究进展</span>

临床肿瘤学杂志 ›› 2018, Vol. 23 ›› Issue (10): 945-951.

• 综述与讲座 • 上一篇    下一篇

Notch信号通路与肿瘤耐药的研究进展

  

  1.  210011  南京  南京医科大学第二附属医院肿瘤科
  • 收稿日期:2018-04-26 修回日期:2018-08-19 出版日期:2018-10-31 发布日期:2019-03-20
  • 通讯作者: 王朝霞 E-mail: zhaoxiawang88@126.com
  • 基金资助:
    国家自然科学基金资助项目(81472198,81272601);江苏省科技厅临床医学科技专项(BL2014096)

 

Progression of Notch signaling pathway and drug resistance in cancer

  1. Department of Oncology the Second Affiliated Hospital of Nanjing Medical University Nanjing 210011
  • Received:2018-04-26 Revised:2018-08-19 Online:2018-10-31 Published:2019-03-20
  • Contact: WANG Zhaoxia. E-mail: zhaoxiawang88@126.com

摘要:  化疗是恶性肿瘤常用的治疗手段之一,但获得性耐药是阻碍患者临床疗效、导致治疗失败的主要原因。Notch信号通路的异常改变不但与恶性肿瘤的发病有关,而且还参与多种恶性肿瘤化疗耐药的形成。Notch信号通路广泛表达于多种肿瘤细胞,通过促进肿瘤干细胞(CSCs)表型、上皮间质转换(EMT)及与其他信号通路串联等途径,导致肿瘤对化疗药物耐药。通过调控Notch信号通路提高肿瘤对化疗药物的敏感性,为肿瘤治疗提供了新思路,具有一定的临床意义。

关键词: font-family:宋体, 肿瘤')">">肿瘤, Notch信号通路, 化学治疗, 耐药

Abstract:  Chemotherapy is an important therapeutic strategy for cancer treatment however chemoresistance is a major challenge. Recently emerging evidences suggest that abnormal changes in the Notch signaling pathway are involved in the development and chemotherapy resistance of human malignancies. Notch signaling pathway is widely expressed in a variety of tumor cells and it promotes tumor stem cell CSC phenotype epithelial-mesenchymal transition EMT), and interaction with other signaling pathways resulting in tumor resistance to chemotherapeutic drug. Therefore this article will provide a brief overview of what is currently known about Notch signaling and its related regulatory mechanism. Moreover down-regulation of Notch pathway could enhance drug sensitivity which may provide a novel approach for the treatment of cancer.

Key words:  , Cancer">Cancer')">">, Notch signaling pathway, Chemotherapy, Drug-resistance

')">">

中图分类号: 

  • 730
[1] 李振淼, 宋 博, 赵 怡.

X射线调强放疗对乳腺癌保乳术后远期生存及免疫功能影响的临床观察 [J]. 临床肿瘤学杂志, 2019, 24(2): 158-162.

[2] 姚佳雨, 吴 霞. 经济毒性:肿瘤分子靶向及免疫治疗时代不可忽视的问题[J]. 临床肿瘤学杂志, 2019, 24(2): 183-187.
[3] 葛 琴, 钱 霞, 谢国栋, 蔡 晶, 杨百霞, 吴建亭, 赵季忠, 崔娟娟, 朱兴华, 储春霞. EGFR和TGF-α在肺癌细胞放疗增敏中的作用[J]. 临床肿瘤学杂志, 2019, 24(2): 145-148.
[4] .  癌症疼痛诊疗规范(2018年版)[J]. 临床肿瘤学杂志, 2018, 23(10): 937-944.
[5] 邢丽君, 黄伟综述, 王琳.  

生物标志物对抗血管生成药物疗效预测作用的进展

[J]. 临床肿瘤学杂志, 2018, 23(10): 952-956.

[6] 许 晶, 李 洁, 张美静, 陈龙佩, 龙 菲, 王 薇, 湛先保. 化疗相关性恶心呕吐的回顾性研究[J]. 临床肿瘤学杂志, 2018, 23(5): 440-443.
[7] 毛海燕, 刘斯平, 张 蕾, 童建东, 卜 平. Neuropilin-1在消化道恶性肿瘤发生发展中的生物学作用[J]. 临床肿瘤学杂志, 2018, 23(5): 467-471.
[8] 梅文娟, 李 新, 武晓燕, 张周龙. 声脉冲辐射力弹性成像技术对甲状腺良恶性结节的鉴别诊断价值[J]. 临床肿瘤学杂志, 2018, 23(5): 444-448.
[9] 刘雨晨, 吴 斌. 国外抗肿瘤药物价值评估体系的概述[J]. 临床肿瘤学杂志, 2018, 23(5): 472-475.
[10] 李 进,曹 君. 大肠癌单克隆抗体治疗新进展[J]. 临床肿瘤学杂志, 2009, 14(1): 1-.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!